U.S. Markets close in 4 hrs 40 mins
  • S&P 500

    +15.02 (+0.40%)
  • Dow 30

    +77.16 (+0.25%)
  • Nasdaq

    +85.79 (+0.66%)
  • Russell 2000

    +25.72 (+1.21%)
  • Crude Oil

    +0.58 (+1.11%)
  • Gold

    +10.40 (+0.57%)
  • Silver

    +0.43 (+1.75%)

    +0.0045 (+0.3760%)
  • 10-Yr Bond

    +0.0040 (+0.36%)
  • Vix

    -1.40 (-5.75%)

    +0.0031 (+0.2261%)

    +0.1890 (+0.1823%)

    +1,212.48 (+3.33%)
  • CMC Crypto 200

    +29.74 (+4.16%)
  • FTSE 100

    +11.48 (+0.17%)
  • Nikkei 225

    +391.25 (+1.39%)

With A 6.5% Return On Equity, Is Pliant Therapeutics, Inc. (NASDAQ:PLRX) A Quality Stock?

Simply Wall St
·4 min read

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of learning-by-doing, we'll look at ROE to gain a better understanding of Pliant Therapeutics, Inc. (NASDAQ:PLRX).

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

View our latest analysis for Pliant Therapeutics

How Do You Calculate Return On Equity?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Pliant Therapeutics is:

6.5% = US$20m ÷ US$300m (Based on the trailing twelve months to September 2020).

The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.07.

Does Pliant Therapeutics Have A Good ROE?

By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. As is clear from the image below, Pliant Therapeutics has a lower ROE than the average (18%) in the Pharmaceuticals industry.


That certainly isn't ideal. That being said, a low ROE is not always a bad thing, especially if the company has low leverage as this still leaves room for improvement if the company were to take on more debt. A company with high debt levels and low ROE is a combination we like to avoid given the risk involved. Our risks dashboard should have the 3 risks we have identified for Pliant Therapeutics.

The Importance Of Debt To Return On Equity

Companies usually need to invest money to grow their profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. Thus the use of debt can improve ROE, albeit along with extra risk in the case of stormy weather, metaphorically speaking.

Pliant Therapeutics' Debt And Its 6.5% ROE

One positive for shareholders is that Pliant Therapeutics does not have any net debt! Even though I don't think its ROE is that great, I think it's very respectable when you consider it has no debt. After all, when a company has a strong balance sheet, it can often find ways to invest in growth, even if it takes some time.


Return on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. Companies that can achieve high returns on equity without too much debt are generally of good quality. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE.

Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. Profit growth rates, versus the expectations reflected in the price of the stock, are a particularly important to consider. So I think it may be worth checking this free report on analyst forecasts for the company.

Of course Pliant Therapeutics may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.